Janjivan Bureau / New Delhi : World Health Organization’s technical advisory group approved for emergency use listing of India’s indigenous Covaxin. Covaxin has become the seventh vaccine to get WHO approval.
The technical advisory group had on October 26 nee to consider emergency use listing for Covaxin and sought additional clarifications.
The WHO had been working closely with Bharat Biotech to complete the dossier.
WHO chief scientist Soumya Swaminathan said that the WHO’s goal was to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere.
Bharat Biotech, the Covaxin manufacturer, has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27.
WHO experts reviewed the information available and Bharat Biotech was learnt to have addressed most of the queries raised by the world body.
Covaxin is an indigenous Indian Covid shot, developed and produced here in private-public partnership by Biotech and ICMR.
Covaxin gets shelf life extension up to 12 months
Vaccine maker Bharat Biotech on Wednesday said the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of its Covid-19 vaccine Covaxin up to 12 months from the date of manufacture.
“The CDSCO has approved the extension of shelf life of Covaxin up to 12 months, from the date of manufacture. This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO,” Bharat Biotech said in a tweet.
The shelf life extension has been communicated to “our stakeholders,” it added.
